Etanercept in the treatment of plaque psoriasis by Thao U Nguyen & John Koo
© 2009 Nguyen and Koo, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical, Cosmetic and Investigational Dermatology 2009:2 77–84 77
REVIEW
Etanercept in the treatment of plaque psoriasis
Thao U Nguyen
John Koo
Department of Dermatology, Psoriasis 
and Skin Treatment Center, University 
of California, San Francisco, San 
Francisco, California, USA
Correspondence: John Koo
UCSF Psoriasis and Skin Treatment 
Center, 515 Spruce Street, San Francisco, 
CA 94143, USA
Tel +1 415 476 4701
Fax +1 415 502 4126
Email john.koo@ucsfmedctr.org
Abstract: Etanercept is approved for the treatment of moderate to severe plaque psoriasis at a 
dose of 50 mg twice weekly for 3 months followed by a maintenance dosage of 50 mg weekly 
thereafter. Clinical studies have shown excellent efﬁ  cacy, favorable beneﬁ  t to side-effects ratio, 
and safe long-term usage. Extensive information on safety is available as etanercept has been 
used for many years for other indications such as rheumatoid arthritis and psoriatic arthritis and 
is the ﬁ  rst of the tumor necrosis factor antagonists to gain approval in psoriasis.
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Introduction
Etanercept (Enbrel®; Amgen-Wyeth) is a fully human tumor necrosis factor (TNF) 
receptor that reduces the inﬂ  ammatory response by inhibiting interactions between 
TNF and cell-surface TNF receptors. Currently three TNF antagonists (adalimumab, 
inﬂ  iximab and etanercept) are approved by the US Federal Drug and Administration 
(FDA) for the treatment of plaque psoriasis. Adalimumab and etanercept are indicated 
in the treatment of moderate to severe plaque psoriasis, whereas inﬂ  iximab is indicated 
for severe plaque psoriasis. Adalimumab and inﬂ  iximab are monoclonal antibodies, 
while etanercept is a soluble receptor fusion protein. Etanercept is also FDA approved 
for rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis (JIA), and 
ankylosing spondylitis (AS).
Etanercept is an important therapeutic option in patients with moderate to severe 
plaque psoriasis. Studies have found it to have a high efﬁ  cacy, favorable beneﬁ  t to 
side-effects ratio, and safe long-term usage compared to other systemic treatments 
for psoriasis such as methotrexate, cycloporine, and PUVA. Effective treatment of 
psoriasis is needed because of the associated morbidity of psoriasis. Quality-of-life 
studies in patients with psoriasis attest to its signiﬁ  cant impact on day to day activities 
and effect on personal relationships.1,2
Patients with psoriasis have increased disease-related inability to work,3 and face 
signiﬁ  cant discrimination with resulting ﬁ  nancial difﬁ  culties and depression.4 Psoriasis 
has also been associated with several comorbid conditions including obesity and car-
diovascular disease.2,5,6 These data have prompted an awareness and interest in more 
aggressive management of psoriasis including biologic agents.
Mechanism of action
Etanercept is a fully soluble, human dimeric fusion protein with a molecular weight of 
150 kDa. It consists of two extracellular ligand-binding domains of the human 75 kDa 
TNF receptor linked to the Fc portion of human immunoglobulin G1 (IgG1) by three 
disulﬁ  de bonds. The protein is produced using recombinant DNA technology in a mam-
malian Chinese hamster ovarian cell line and consists of 934 amino acids.7,8 Despite 
the presence of an Fc region, etanercept does not promote complement-mediated cell 
lysis in vitro as opposed to the monoclonal antibodies that do exhibit this in vitro.9 Clinical, Cosmetic and Investigational Dermatology 2009:2 78
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Etanercept acts as a competitive inhibitor of TNF, a naturally 
occurring proinﬂ  ammatory cytokine produced by many 
different cell types including activated T cells, ﬁ  broblasts, 
adipocytes, and keratinocytes. TNF acts as a key mediator 
of inﬂ  ammatory processes in the pathogenesis of psoriasis 
and psoriatic arthritis.
Etanercept inhibits the activity of TNF by competitively 
binding it, thus antagonizing interactions with TNF receptors 
on cell surface, and preventing activation of the inﬂ  ammatory 
cascade. It is unique among TNF blocking biologic agents for 
psoriasis in that it mimics the activity of naturally occurring 
soluble TNF receptors, and prevents binding of free, soluble, 
non-membrane-bound TNF. There are two distinct receptors 
for naturally-occurring TNF: p55, also known as TNF-β or 
lymphotoxin, and p75, which is TNF-α. Biological activity 
of TNF is modulated through these receptors.10–12
Elevated levels of TNF-α have been found in ﬂ  uid from 
patients with psoriatic arthritis, psoriatic skin lesions, and 
serum of patients with plaque psoriasis.13 TNF-α stimulates 
the production of chemokines and the expression of adhesion 
molecules by keratinocytes and vascular endothelial cells. 
The release of these signals cause recruitment of additional 
inﬂ  ammatory cells into the plaque, amplifying the inﬂ  am-
matory process within psoriatic plaques.14 Treatment with 
etanercept has been shown to reduce several markers of 
inﬂ  ammation within biopsied plaques.15 Moreover, serum 
and lesional TNF-α levels directly correlate with the severity 
of psoriasis, as measured by the psoriasis area and severity 
index (PASI) score.16,17 Additionally, the dimeric nature of 
etanercept protein allows the binding of TNF-α at an afﬁ  nity 
that is 50 to 1000 times greater than in naturally occurring 
TNF-α receptors.8
Etanercept may also weakly interact with the TNF-β 
receptor, which acts on B-cells, T-cells, NK-cells and lym-
phoid architecture to stimulate immunoreactivity.10,11 TNF-β 
inhibition has been shown to be effective in moderating the 
symptoms of psoriasis. However, onercept, a human recom-
binant soluble TNF-β receptor, was discontinued in April 
2005 during Phase III clinical trials for moderate to severe 
psoriasis after two patients developed sepsis.18
Pharmacokinetics
Etanercept has a mean half-life of approximately 4.3 days 
(70–100 hours) and reaches peak concentration at approxi-
mately 48 to 60 hours with an absolute bioavailability of 
58%.19 Of the currently marketed anti-TNF agents approved 
for psoriasis, etanercept exhibits the shortest half-life. 
Potential advantages incurred by the shorter half-life can 
include more rapid drug elimination in the setting of a serious 
adverse event including an infectious episode. No formal 
pharmacokinetics studies have been conducted to investigate 
the metabolism of etanercept. However, using radiolabelled 
etanercept in patients with acute renal and hepatic failure 
did not demonstrate abnormally increased serum etanercept 
concentrations. Therefore, no dosage adjustment is needed 
in the presence of renal and hepatic impairment.20 There are 
no apparent age- or gender-related pharmacokinetic differ-
ences. However, in children aged 4 to 8 years, the clearance 
of etanercept may be slightly reduced though no dose adjust-
ment is warranted.19,21,22 Furthermore, no dose adjustment is 
needed when etanercept is co-administered with methotrex-
ate, warfarin, or digoxin.23–25
Indications and dosing
In the United States, etanercept is indicated for the treatment 
of adult patients (18 years or older) with chronic moderate 
to severe plaque psoriasis who are candidates for systemic 
therapy or phototherapy.9 The recommended induction dose 
of etanercept in the treatment of moderate-to-severe plaque 
psoriasis is 50 mg twice weekly for 3 months followed by 
a maintenance dosage of 50 mg weekly.26 There are data 
to demonstrate once-weekly administration of etanercept 
50 mg is as efﬁ  cacious and well tolerated as etanercept 25 mg 
biweekly providing a more convenient dosing regimen.27
In Europe, etanercept is indicated for the treatment of 
adults with chronic moderate to severe plaque psoriasis 
who have failed to respond to, or who have a contraindica-
tion to, or who are intolerant to other systemic therapies or 
photochemotherapy including cyclosporine, methotrexate or 
PUVA.28 It is also indicated in the treatment of active and 
progressive psoriatic arthritis in adults who have failed dis-
ease-modifying anti-rheumatic drug (DMARD) therapy. The 
European dermatology expert group recommends the same 
dosing regimen as the one used in the US for the treatment 
of plaque psoriasis.29
Monotherapy
Etanercept has been shown to be effective as monotherapy for 
moderate to severe plaque psoriasis with dose dependent efﬁ  -
cacy.26,30–38 Published data from large randomized control trials 
conducted by various investigators from the Etanercept Psoria-
sis Study Group have found that at 12 weeks, 34% of patients 
receiving 25 mg of etanercept biweekly (biw) and 47% to 49% 
of patients receiving 50 mg biw, had improvement of PASI 75 
from baseline compared with 3% to 4% of patients receiving 
placebo.30–32 This response is dose dependent with faster and Clinical, Cosmetic and Investigational Dermatology 2009:2 79
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more signiﬁ  cant responses occurring in patients taking 50 mg 
biw.30,31 Papp et al30 in their Phase III trial of 583 patients 
reported that by week 4, only the 50 mg biw group had a 
statistically signiﬁ  cant number of people (10%) achieving PASI 
75, while the 25 mg biw group achieved statistical signiﬁ  cance 
at week 8. At week 12, the difference between the etanercept 
50 mg biw group and the 25 mg biw group were statistically 
signiﬁ  cant with a greater response of 47% compared to 34% 
of patients with PASI 75, respectively.30,31
Clinical response may continue to improve or be main-
tained with sustained etanercept therapy. Evidence from 
the two large Phase III randomized-controlled trials (RCT) 
with 6 months follow-up of patients continuing treatment 
found that 44% to 45% of patients receiving 25 mg biw 
and 54% to 59% of patients receiving 50 mg biw achieved 
PASI-75.30,31 Sustained treatment up to 96 weeks in an open-
label extension of a large (n = 591) RCT showed that long-
term etanercept 50 mg biw can maintain psoriasis response.39 
The percent of patients who achieved PASI 75 was 47% at 
12 weeks, 60% at 24 weeks, 63% at 48 weeks, and 51% 
at 96 weeks.
There is evidence from Papp et al that decreasing 
the 50 mg biw dose to 25 mg biw at 12 weeks results in 
maintenance of beneﬁ  ts and even improved response in some 
patients.30 They found that stepped down treatment from 
50 mg to 25 mg biw after 12 weeks of treatment, resulted 
in 54% of patients with PASI-75 at 24 weeks compared to 
45% of patients who had received 25 mg biw for 24 weeks. 
77% of patients were able to maintain a PASI 75 score and 
97% maintained a PASI score greater than 50% while on 
the reduced etanercept dose. Additionally, about one third 
of the 88 people who did not achieve a PASI 75 score at 
12 weeks while taking 50 mg biw did at 24 weeks despite 
the decrease in dose.30
These data suggest that most people may beneﬁ  t from 
the faster, more effective resolution at the higher dose of 
50 mg biw, and will be able to maintain the beneﬁ  ts of 
etanercept induction dose while only taking 25 mg biw after 
the 12 weeks. In patients who do demonstrate loss of clini-
cal response when transitioned from 50 mg to 25 mg BIW, 
ineffective dosing of patients with higher body mass index 
(BMI) may account for some of these cases.40 In general, 
obese patients (BMI greater than 30) are poorer responders. 
Studies have shown that adipose tissue produces elevated 
levels of TNF-α.41 Since patients that are obese have more 
adipose tissue than non-obese patients, it is believed that 
obese patients have elevated TNF-α levels and thus the 
etanercept dose is more often inadequate.
A recent study evaluated the use of etanercept in children 
and adolescents (4–17 years of age) with moderate to severe 
plaque psoriasis. Patients were dosed once weekly with 
0.8 mg/kg of etanercept up to a maximum of 50 mg weekly. 
The percent of patients who achieved a PASI 75 response 
from baseline was 57% compared to 11% in those patients 
receiving placebo (p  0.001).42
Combination therapy
The concept of maximizing efﬁ  cacy and minimizing adverse 
side effects through the combined use of topical, photo-
therapy, and systemic agents has been exercised extensively. 
Combination therapy is most useful to treat patients who 
have failed monotherapy and in the prevention of step-down 
deterioration. Treatment with prebiologic agents is limited 
to rotational therapy due to concerns of cumulative toxicity 
and major organ adverse side effects; the advent of biologic 
agents has increased feasibility of continuous therapy for 
long-term control, particularly in patients with recalcitrant 
disease. Additive immunosuppression may be a concern. For 
this reason, biologics including etanercept are not routinely 
used in combination with drugs such as cyclosporine.
Etanercept and topical corticosteroids
A consensus statement from the European dermatology 
expert group on the use of etanercept encourages the use 
of topical corticosteroids in combination with etanercept, 
particularly at the start of therapy to increase the speed 
of therapeutic response.29 Combination of etanercept with 
phototherapy is of greater concern due to etanercept’s 
immunosuppressive side effects and phototherapy’s possible 
increased risk of skin cancers. Although there are no data 
on the concomitant use of etanercept and PUVA, this 
combination should only be used with caution in fair-skinned 
patients as the increased risk of skin cancers has been 
demonstrated in patients receiving cyclosporine who were 
previously treated with PUVA.43,44
Etanercept and narrowband ultraviolet 
light B (NBUVB)
A multicenter, open-label, single-arm prospective study (the 
Utilization of NB-UVB Light Therapy and Etanercept for the 
Treatment of Psoriasis [UNITE] study) evaluated the efﬁ  -
cacy of etanercept 50 mg twice weekly in combination with 
NB-UVB 3 times weekly in patients with moderate to severe 
psoriasis (n = 86).45 After 12 weeks, the percent of patients 
achieving a PASI 75 response was 84.4%. The percentage of 
patients who achieved a PASI 90 or PASI 100 response was Clinical, Cosmetic and Investigational Dermatology 2009:2 80
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58.1% and 26%, respectively. In this study, the combination 
of etanercept and NB-UVB was efﬁ  cacious and generally 
well tolerated with no increase in photosensitivity noted. The 
addition of NB-UVB may serve as an option for the subset 
of patients who experience worsening of psoriasis after 
“stepping-down” from the induction dose. Caution should 
be used when starting etanercept for patients with known or 
suspected skin cancers due to case reports of squamous cell 
cancers (SCCs) that grew rapidly from pre-existing suspi-
cious lesions after initiation of etanercept therapy.46
Etanercept and methotrexate
Most data involving the combination of etanercept with 
DMARDs, particularly, methotrexate are from rheumatology 
in the treatment of rheumatoid arthritis and psoriatic arthritis. 
The safety of this combination has been evaluated in rheu-
matoid arthritis in two large randomized, controlled, double-
blind clinical trials: the Trial of Etanercept and methotrexate 
with Radiographic Patient Outcomes (TEMPO)47 (n = 682) 
and the Combination of Methotrexate and Etanercept in 
Active Early Rheumatoid Arthritis (COMET)48 (n = 542). 
Each study found the combination of methotrexate and 
etanercept to be generally safe and well-tolerated with no 
statistically signiﬁ  cant increased rates and types of adverse 
events compared to the monotherapy groups.
Etanercept is approved for the treatment of both psoria-
sis and psoriatic arthritis. Clinical trials involving psoriatic 
arthritis allow concurrent use of systemic agents including 
methotrexate and prednisone. However, trials in psoriasis 
population often require that patients “wash out” from such 
medications, thus most available data on combination therapy 
are from case reports.49–52
Recently, Zachariae and colleagues53 conducted a 24-week 
RCT evaluating combination therapy with etanercept and 
methotrexate in 59 patients with plaque psoriasis who had 
previously failed methotrexate monotherapy. Patients were 
randomized into two groups, one which received etanercept 
with methotrexate tapered up to week 4, and the other received 
etanercept combined with continued methotrexate treatment. 
In both arms, patients received etanercept 50 mg twice weekly 
for 12 weeks, and then 25 mg twice weekly for the remaining 
12 weeks. The study reported a signiﬁ  cantly higher proportion 
of patients achieving a PGA of “clear” or “almost clear” and 
PASI 50, PASI 75, and PASI 90 at both 12 weeks and 24 weeks 
for combination treatment than etanercept/methotrexate taper. 
There was very little difference in adverse events in patients 
receiving combination therapy versus etanercept monotherapy. 
The combination of methotrexate with etanercept offers 
a promising option for patients suffering from psoriasis despite 
monotherapy with methotrexate or etanercept.
Etanercept and acitretin
There are few studies evaluating the efﬁ  cacy of acitretin with 
biologics. One case series described eight patients who had 
been treated with biologic agents and acitretin.54 Five of the 
eight patients received treatment with etanercept (25–50 mg 
once to twice weekly) and acitretin (25–50 mg every other 
day to daily). One of these patients was later changed to 
adalimumab 40 mg weekly plus acitretin. Other than mild 
transient cholesterol elevation in one patient, there were no 
reported adverse effects.
A retrospective review (n = 15) described patients 
treated with acitretin and a biologic agent, four received 
etanercept.45 The average time of treatment with both agents 
was 7.28 months. Overall, 29% of patients were clear of 
psoriasis, 43% showed 90% improvement, 14% showed 75% 
improvement, and 7.15% showed no change. One patient with 
a previous history of SCC continued to develop multiple SCCs 
while on etanercept therapy. After acitretin (25 mg every other 
day) was added, the rate of new SCC development decreased 
from an average of three SCCs diagnosed every two weeks to 
actinic keratosis with no new SCCs for 18 months. Another 
patient who was treated with acitretin and etanercept for 3 years 
developed non-Hodgkin’s lymphoma, at which point etanercept 
was discontinued. The authors concluded that acitretin may be 
useful in combination with biologic agents, but further studies 
to determine the long-term safety and efﬁ  cacy were needed.
A randomized, investigator-blinded pilot trial treated 
60 patients with either etanercept 25 mg twice weekly, 
acitretin 0.4 mg/kg daily, or etanercept 25 mg once weekly 
plus acitretin 0.4 mg/kg daily.55 The PASI 75 response 
after 24 weeks was 45% in the etanercept group, 30% in 
the acitretin group and 44% in the combination group. No 
signiﬁ  cant differences in the mean value of liver enzymes, 
cholesterol, and triglycerides were reported in any of the three 
groups at all times investigated. The results from this study 
demonstrated that combination of acitretin and etanercept 
may serve as another long-term control option for psoriasis, 
or alternatively, etanercept could be added in patients inad-
equately treated with acitretin monotherapy. This combination 
greatly reduces the cost of treatment compared with etanercept 
25 mg twice weekly while achieving similar efﬁ  cacy.
Toxicities and adverse reactions
Etanercept has been used worldwide in over half a million 
patients, with chronic conditions such as severe arthritis or Clinical, Cosmetic and Investigational Dermatology 2009:2 81
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psoriasis for more than 16 years. Etanercept has undergone 
numerous short-term safety analyses in rigorous clinical trials 
in rheumatoid arthritis, psoriatic arthritis, and psoriasis and 
long-term safety analyses in both controlled clinical trials 
and post-marketing surveillance.10,31,56,57 Despite this long-
term and extensive human experience, to date, the FDA has 
not reported any serious adverse events based on evidence-
based, Grade A criteria (ie, statistically slight increased 
risk when comparing large etanercept treated population vs 
placebo treated population involving subjects who are basi-
cally healthy and not a carrier of chronic infection such as 
tuberculosis [TB] or hepatitis).
Injection site reaction
The most common adverse effect of etanercept appears to be 
a mild, transient injection site reaction, generally occurring 
during initial administration lasting between 3 and 5 days. 
Approximately, 37% of patients will experience this side 
effect. Appropriate medication administration including 
rotation of sites should be discussed with patients at teach-
ing session.
Infections
The next most common side effect is an increased risk of 
infections, particularly upper respiratory tract infections 
and cold-like illnesses. Patients may have increased 
susceptibility to infections by intracellular organisms 
including TB and listeria. However, there is no evidence-
based data demonstrating increased TB reactivation in 
etanercept users compared to the general population 
unlike TNF-monoclonal antibodies.33,46,47 Some studies 
demonstrate that TB reactivation in etanercept users has an 
increased risk of presenting as an atypical or disseminated 
infection.58 In contrast to etanercept, adalimumab and 
inﬂ  iximab are monoclonal antibodies that bind to soluble 
and transmembrane TNF-α and may cause complement-
mediated cell lysis of macrophages and monocytes; 
therefore, they appear to interfere to a greater extent with the 
host granulomatous defense against intracellular organisms 
such as TB.
The FDA, in their post-marketing surveillance data-
base has recently strengthened their black box warning on 
all TNF-antagonists for fungal infections, with a speciﬁ  c 
focus on histoplasmosis. Of the 240 reports of histoplas-
mosis in patients receiving TNF-antagonists submitted 
to the FDA, 17 cases were related to etanercept (7%), 
with the rest related to inﬂ  iximab (207 cases; 86%) and 
adalimumab (16 cases; 6.6%). Patients from the endemic 
Ohio and Mississippi River valley regions made up 80% 
of these cases.59
Long-term follow up of etanercept therapy up to 96 weeks 
found that exposure-adjusted rates of noninfectious and 
infectious adverse events were similar between the treatment 
group at weeks 12 and 96, and between the treatment group 
and placebo.39
Hepatitis B
There have been case reports of hepatitis B virus (HBV) 
reactivation in patients who are chronic carriers while receiv-
ing etanercept.9,60 The incidence of HBV reactivation is 
higher in patients receiving concomitant immunosuppressive 
therapy.9,60 Currently, the safety or efﬁ  cacy of treating patients 
who are HBV carriers with anti-viral therapy in conjunction 
with TNF-α antagonists to prevent HBV reactivation is not 
known. Caution should be taken when etanercept is consid-
ered in patients who are carriers of HBV.
Hepatitis C
In contrast to its effects on HBV, there have been case reports 
of etanercept use in patients with concurrent hepatitis C 
virus infection without worsening of hepatitis or interfering 
with hepatitis treatment.61 Etanercept is not indicated for 
the treatment of chronic HCV although there has been one 
phase II randomized controlled study evaluating etanercept 
use in patients with chronic HCV. Etanercept was given 
as an adjuvant to interferon and ribavirin in 50 patients 
with chronic HCV with reports of an increased virologic 
response at week 24 (etanercept 63% vs placebo 32%) and 
no statistically signiﬁ  cant differences in hematological 
adverse effects.62 Furthermore, there have been case reports 
that etanercept may be a safe option for treating psoriatic 
arthritis and psoriasis in patients with concurrent chronic 
HCV infection.63
Others
Serious infections and sepsis, including fatalities, have 
been reported in patients undergoing etanercept therapy.9 
There is a greater risk of mortality in patients who become 
septic while receiving etanercept.64,65 Several of the seri-
ous infections have occurred in patients on concomitant 
immunosuppressive therapy that, in combination with their 
underlying disease, may predispose this patient population 
to infections. It is advised that etanercept should be discon-
tinued until resolution of serious infection or sepsis. Fur-
ther, serious adverse events such as demyelinating disease, 
congestive heart failure, hematological abnormalities, and Clinical, Cosmetic and Investigational Dermatology 2009:2 82
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systemic lupus-like condition are rare and primarily based 
on anecdotal evidence.64,65
Another consideration for patients treated with long-term 
TNF-α antagonists, including etanercept, is the possibility of 
increased weight gain.66,67 Additionally, etanercept antibodies 
may be encountered in up to 16% of patients;68 however these 
antibodies are non-neutralizing and do not appear to effect 
efﬁ  cacy or safety proﬁ  les.9
Malignancy
The incidence of malignancy was investigated in the 96-week 
trial of etanercept39 and compared to the incidence of cancer 
in the population. The authors found 9 malignancies during 
the open-label follow up and compared the incidence to 
national cancer databases. Observed numbers of total 
malignancies were not statistically signiﬁ  cantly different 
from the expected numbers of total malignancies based on 
National Cancer Institute data.39
The FDA recently issued an Early Communication 
regarding the possible association between TNF blockers 
and the development of lymphoma and other malignancies in 
children and young adults. Over a 10-year interval, beginning 
in 1998 through 2008, there were approximately 30 reports of 
cancer occurring in children and young adults who began taking 
TNF inhibitors (along with other immunosuppressive medica-
tions such as methotrexate, azathioprine or 6-mecaptopurine), 
when they were aged 18 or less. Approximately half of the 
cancers reported were lymphoma. At the current time, the FDA 
believes that the potential beneﬁ  ts of TNF inhibitors outweigh 
the potential risks but further long-term studies are necessary 
to provide deﬁ  nitive answers about whether the use of TNF 
inhibitors in children increase the occurrence of cancers.69
Pregnancy
Etanercept and other TNF-α antagonists are considered 
category B drugs for pregnancy. Limited data are available 
on the safety of etanercept in pregnant or lactating patients. 
Because animal reproductive studies are not always predic-
tive of human response, this drug should not be used in 
pregnancy unless clearly needed. It is not known whether 
etanercept is absorbed systemically after ingestion and so 
there is a potential for serious adverse reactions to the nursing 
infant. A decision should be made whether to discontinue 
etanercept before nursing. There is no evidence support-
ing embryo toxicity, teratogenicity or increased pregnancy 
loss.70,71 Currently, there are no studies describing the effect 
of etanercept on human lactation or the nursing infant. 
Thus, the use of etanercept during pregnancy and lactation 
is not recommended. Caution is advised when prescribing 
to women of reproductive age.72
Follow-up
A baseline and annual Mantoux test using puriﬁ  ed protein 
derivative (PPD) is required to monitor for TB. Although 
widely used, the PPD test has a number of limitations including 
lack of sensitivity in immunocompromised and active TB 
patients and lack of speciﬁ  city in bacille Calmette-Guérin 
(BCG)-exposed individuals. Two novel FDA approved assays 
for detecting latent TB can be considered. The QuantiFERON®-
TB Gold test (QFT-G; Cellestis Ltd, Carnegie, Australia) and 
T-Spot® TB (Oxford Immunotec, Abingdon, UK) may offer 
greater sensitivity and speciﬁ  city than Mantoux test, espe-
cially in context of immunosuppression and previous BCG 
vaccination.73 Preliminary studies using QFT-G in screening for 
TB in rheumatoid arthritis patients undergoing TNF-inhibitor 
therapy has suggested that it is sensitive for detecting latent TB 
in patients previously exposed to various immunosuppressive 
therapies at the time of the QFT-G testing.74
Complete blood count and liver function tests may also 
be obtained at baseline with periodic monitoring. History and 
physical examination should be obtained while a patient is 
on this medication. Due to reports of hepatitis B reactivation, 
screening for hepatitis B and C should be considered in the 
appropriate clinical setting.
Guidelines for use
1.  Etanercept is indicated for patients with moderate to 
severe psoriasis, adult and juvenile idiopathic (formerly 
rheumatoid) arthritis (for patients as young as 4 years of 
age), and ankylosing spondylitis.
2.  Psoriatic arthritis dosing is 25 mg twice weekly or 50 mg 
weekly, given subcutaneously.
3.  PPD testing should be performed on all patients prior to 
starting therapy.
4.  Live vaccines should not be used in combination with 
etanercept or other TNF inhibitors. Biologically inactive 
or recombinant vaccines may be used; however patients 
should be warned the immune response to these vaccines 
may be compromised.
5.  Etanercept should not be used in patients with a history of 
multiple sclerosis or other demyelinating diseases. First 
degree relatives of patients with multiple sclerosis also 
should not use etanercept.
6.  Etanercept should be used with caution in patients with 
congestive heart failure (CHF). Patients with New York 
Heart Association class III or IV CHF should not use Clinical, Cosmetic and Investigational Dermatology 2009:2 83
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TNF inhibitors. Patients with New York Heart Associa-
tion class I or II CHF should undergo echocardiogram 
testing. If their ejection fraction is 50%, etanercept 
should not be used.
7.  Due to reports of hepatitis B reactivation after starting 
etanercept, screening for hepatitis B infection should be 
performed in the appropriate clinical setting.
8.  Etanercept is pregnancy category B and should only be 
used during pregnancy if clearly needed.
9.  Etanercept is contraindicated in patients with sepsis or 
other active, serious infections.
10. The needle cover of the preﬁ  lled syringes contains latex 
and should not be used in patients with latex sensitivity.
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